GLP-1 receptor agonists modulate brain glutamate signaling, and their appetite-suppressing effects depend on specific glutamate receptor pathways.
31 preclinical studiesAll showing GLP-1 receptor agonists modulate glutamate signaling, but zero human studies exist yet
What the researchers found
Across 31 preclinical and pharmacologic studies, GLP-1 receptor agonists were consistently associated with increased glutamate release, activation of NMDA and AMPA receptors, and enhanced release of neurotrophic factors linked to neurogenesis, neurodifferentiation, and synaptic plasticity. Crucially, the food intake suppression caused by GLP-1 RAs was found to be dependent on AMPA receptor signaling but not NMDA receptor signaling, suggesting a specific mechanistic pathway for the anti-obesity effects of these drugs.
Why it matters
GLP-1 receptor agonists like semaglutide are among the most prescribed drugs worldwide for obesity and diabetes. Understanding exactly how they work in the brain — particularly their interaction with glutamate, which accounts for 90% of excitatory neurotransmission — could open doors to new neuropsychiatric applications and help explain both their therapeutic benefits and potential side effects.
How the study worked
The researchers conducted a systematic review of studies published across PubMed, Ovid, and Scopus databases from inception through March 2025. Two independent reviewers screened studies using the Covidence platform. They included in vitro, in vivo, and pharmacologic studies, ultimately identifying 31 studies that met eligibility criteria. No human clinical studies were found.
What this study cannot tell us
No human clinical studies were available for inclusion, so all findings come from preclinical (animal and cell-based) research. Results from animal models don't always translate directly to humans. The review also did not assess the quality or risk of bias of included studies in detail, and publication bias toward positive results may influence the overall picture.
How to read the evidence
As a systematic review of preclinical studies with no human data, this provides a strong mechanistic foundation but cannot yet confirm clinical relevance in humans.
When this study was published
Published in 2026, this is a very recent review incorporating literature through March 2025, making it current and comprehensive for the preclinical evidence base.
The bigger picture
As GLP-1 receptor agonists become blockbuster drugs for obesity and diabetes, researchers are uncovering that their effects extend far beyond blood sugar and appetite. This review reveals a significant crosstalk between GLP-1 and glutamate systems in the brain, suggesting these drugs may have untapped potential for treating neuropsychiatric disorders — an area of active research interest.
Questions still open
- Could GLP-1 receptor agonists be repurposed for neuropsychiatric conditions like depression or addiction based on their glutamatergic effects?
- Why does GLP-1's effect on appetite depend on AMPA but not NMDA receptors, and what does this mean for drug development?
- Will the glutamate-related effects seen in animal models hold up in human clinical trials?
Common questions
How do GLP-1 drugs like semaglutide affect brain signaling?
Could GLP-1 drugs be used for brain disorders beyond obesity?
Read the original research
Investigating the functional connectivity between central glucagon-like peptide-1 (GLP-1) and glutamatergic signaling: a systematic review.
CNS spectrums, 31(1), e4
Citation
Wong, Sabrina; Le, Gia Han; Teopiz, Kayla; McIntyre, Roger S. (2026). Investigating the functional connectivity between central glucagon-like peptide-1 (GLP-1) and glutamatergic signaling: a systematic review.. CNS spectrums, 31(1), e4. https://doi.org/10.1017/S1092852926100844